The World's First Periwound Neuropathy Therapeutic System.

Repairs NERVES, MUSCLE AND VASCULATURE

Rapid Nexus Nanotech Wound Solutions, Inc. is a California-based medical device company developing regenerative technology that targets the root causes of chronic wounds. Its patented technology is the first to restore nerve function and circulation to prevent amputations and enable full recovery in patients with diabetes, trauma, and peripheral vascular disease.

Led by Dr. Kalmeta, our dedicated team is committed to expanding access to this life-changing technology. 

The World's First Periwound Neuropathy Therapeutic System.

Repairs NERVES, MUSCLE AND VASCULATURE

Rapid Nexus Nanotech Wound Solutions, Inc. is a California-based medical device company developing regenerative technology that targets the root causes of chronic wounds. Its patented technology is the first to restore nerve function and circulation to prevent amputations and enable full recovery in patients with diabetes, trauma, and peripheral vascular disease.

Led by Dr. Kalmeta, our dedicated team is committed to expanding access to this life-changing technology. 

0 M

Americans

Suffer from chronic wounds
each year

0

Amputations daily

Every 20 seconds, a limb is
amputated due to chronic
wounds

0 %

Mortality rate

Patients die after five years of the first amputation

The Market
Problem

  • There are currently zero products made to repair nerve damage caused by peripheral neuropathy in complex non-healing wounds.

  • Since competitor products have no therapeutic effect on neuropathy, wounds progress to chronic and non-healing types where microbes fester.

  • ADA data shows that after 3 months of treatment, about 25% of wounds persist even after 1 year of treatment.

  • Patients are in danger of an amputation, sepsis, and death.

Learn More About Our Results

 

Repair of multi-year-old non-healing chronic wounds. Our groundbreaking unique formula accelerates the healing process, promoting cell regeneration and reducing inflammation. 

Our Mission

“Our mission is to give doctors the advanced tools they need in order to treat infection, close non-healing wounds and prevent amputations, which are especially prevalent in the disproportionately affected populations.”

Unlike competing products that just protect the tissue, Dr. Kalmeta developed a top-down approach that rebuilds the surrounding tissue and then works its way back into the bed of the wound.

This method stems from her background as an oral surgeon, where she invented a post-surgical rapid healing technology to help heal patients’ periodontal tissue damage and gum infections.

While working to get this product out to market, she met a diabetic man who lost all of his limbs due to amputation.

“I met a diabetic patient in the nursing home who just had all of his limbs amputated from nonhealing wounds. I couldn’t believe what I was seeing, they seemed like simple wounds but ended up destroying his ability to live” – Dr. Kalmeta.

This pushed Dr. Kalmeta to lead a self-funded international effort to adapt her mouth infection technology to the advanced wound market, where it has already prevented numerous amputations.

Meet the Team

Dr. Margaret Kalmeta

FOUNDER & CHIEF EXECUTIVE OFFICER

Dr. Margaret Kalmeta is a doctor of dental surgery with decades of oral surgery clinical practice.  Building and successfully exiting several startup practices, she went on to develop and patent novel tissue and bone growth technologies which were 500% faster in jawbone healing. Learning that amputations measured over 1,000 per day in the US alone, Dr. Kalmeta transferred her technology to the neuropathy and diabetic foot market to address this critical unmet patient need.

Christine Pasciak

CHIEF OPERATIONS OFFICER

Christine Pasciak has formed strategic relationships, alliances, and successfully exited several successful businesses since 1998. Christine has, in total, over 30 years of experience in the health science field, from having a clinical background to being a management executive. As COO for Rapid Nexus, Christine has formed strategic relationships and alliances and built our manufacturing capabilities to scale our technology.​

Brian E. Cain

BOARD MEMBER

Brian E. Cain has over twenty years of commercialization planning and execution for companies such as Shering-Plough (acquired by Merck), Organon (acquired by Schering), Bayer products (acquired by Shering), Pharmacia (acquired by Pfizer), Celgene (acquired by BMS) where he proactively created Commercial and Market Research Digital teams that leveraged analytics and market intelligence to penetrate new markets. Other noteworthy commercialization goals were achieved for Ortho-McNeil and Bristol-Myers Squibb.​

Deepak Sahu, MBA, MPH

BOARD MEMBER

Deepak Sahu is the former managing partner at Alira Health and current managing director at Trinity Life Sciences. Deepak works closely with strategic investors, private equities, and medical devices companies at various stages of maturity and leads acquisition efforts. He sold Kerecis for $1.3B to Coloplast in 2023 and also has acquired and led numerous growth strategies and investment projects. Deepak has an MBA in International Management and MPH in Health Management from Harvard T.H. Chan School of Public Health.

Malcolm St. John

CFO Investor

Over 23 years of experience managing funds across multiple jurisdictions including, Luxembourg and Ireland, where he oversaw assets exceeding $1 billion. Served as CFO at ForumPay and Roivios.

Dr. Margaret Kalmeta

FOUNDER & CHIEF EXECUTIVE OFFICER

Dr. Margaret Kalmeta is a doctor of dental surgery with decades of oral surgery clinical practice.  Building and successfully exiting several startup practices, she went on to develop and patent novel tissue and bone growth technologies which were 500% faster in jawbone healing. Learning that amputations measured over 1,000 per day in the US alone, Dr. Kalmeta transferred her technology to the neuropathy and diabetic foot market to address this critical unmet patient need.

Christine Pasciak

CHIEF OPERATIONS OFFICER

Christine Pasciak has formed strategic relationships, alliances, and successfully exited several successful businesses since 1998. Christine has, in total, over 30 years of experience in the health science field, from having a clinical background to being a management executive. As COO for Rapid Nexus, Christine has formed strategic relationships and alliances and built our manufacturing capabilities to scale our technology.​

Brian E. Cain

BOARD MEMBER

Brian E. Cain has over twenty years of commercialization planning and execution for companies such as Shering-Plough (acquired by Merck), Organon (acquired by Schering), Bayer products (acquired by Shering), Pharmacia (acquired by Pfizer), Celgene (acquired by BMS) where he proactively created Commercial and Market Research Digital teams that leveraged analytics and market intelligence to penetrate new markets. Other noteworthy commercialization goals were achieved for Ortho-McNeil and Bristol-Myers Squibb.​

Deepak Sahu, MBA, MPH

BOARD MEMBER

Deepak Sahu is the former managing partner at Alira Health and current managing director at Trinity Life Sciences. Deepak works closely with strategic investors, private equities, and medical devices companies at various stages of maturity and leads acquisition efforts. He sold Kerecis for $1.3B to Coloplast in 2023 and also has acquired and led numerous growth strategies and investment projects. Deepak has an MBA in International Management and MPH in Health Management from Harvard T.H. Chan School of Public Health.

Malcolm St. John

CFO Investor

Over 23 years of experience managing funds across multiple jurisdictions including, Luxembourg and Ireland, where he oversaw assets exceeding $1 billion. Served as CFO at ForumPay and Roivios.

Why Our Work Matters​

Every 22 seconds, a limb is amputated somewhere around the globe due to a non-healing wound. In the US, 1,380 people undergo amputations daily, due to diabetes. These diabetic non-healing wounds are primarily caused by one underlying condition: neuropathy.

This technology is set to disrupt the $13 billion global peripheral neuropathy and diabetic foot ulcer markets that are expected to nearly double by 2032 due to rising rates of diabetes.

Testimonials

Clinical Perspectives From Experienced Wound Care Professionals

Clinicians with decades of wound care experience are reporting healing outcomes they haven’t previously seen in chronic and non-healing cases. Steve Brown, RN, shares that Rapid Nexus is “redefining what’s possible in wound care,” noting that after more than 20 years in the field, the healing results he’s seeing with Hemastyl are some of the most impressive of his career. He describes the outcomes as consistently remarkable and a breakthrough for patients who need it most.

Dr. Linda Stewart, who has spent over 20 years caring for complex wounds, explains that traditional approaches often manage wounds without truly moving them toward resolution. Since working with Rapid Nexus over the past year, she has seen meaningful progress in patients who previously showed little to no improvement with standard therapies, and even reports preventing at least one amputation during early-stage feasibility work.

According to Dr. Stewart, this technology has the potential to reshape how clinicians think about wound healing, and she expresses pride in collaborating with Dr. Kalmeta and the Rapid Nexus team as the work continues to advance.

Explore real patient outcomes from our clinical use cases.

These examples show how Hemastyl has been used in real clinical settings to support healing in challenging wounds. Each timeline reflects the patient’s individual course under physician care. Images are shared with permission.

View Case Studies